Revised modelling for canagliflozin 300 mg SBP effect

The corollaries of tables 10 and 12 of the AG 8 Feb 2016 response to the ACD comments for the comparison with pioglitazone are as below.

Table 01: AG base case estimates: Canagliflozin 300mg vs PIO

	Net cost	No BMI	BMI 1	BMI 2	BMI 3	BMI 4	BMI 5
Old SBP							
Net cost/QALY	£5,132	-0.004	0.168	0.079	0.095	0.008	0.038
ICER		DOM	£30,537	£65,345	£53,870	£635k	£134k
New SBP							
Net cost/QALY	£4,991	0.013	0.185	0.095	0.112	0.025	0.055
ICER		£385k	£27,003	£52,432	£44,590	£201k	£90,653

Table 02: AG SA09: Canagliflozin 300mg vs PIO

	Net cost	No BMI	BMI 1	BMI 2	BMI 3	BMI 4	BMI 5
Old SBP							
Net cost/QALY	£5,567	-0.020	0.142	0.053	0.081	-0.008	0.047
ICER		DOM	£39,254	£106k	£68,810	DOM	£120k
New SBP							
Net cost/QALY	£5,444	-0.003	0.158	0.069	0.097	0.008	0.063
ICER		DOM	£34,442	£79,183	£56,087	£658k	£86,694